Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New semicarbazide-sensitive amine oxidase inhibitors disclosed by Hungarian researchers

April 12, 2010

Long-term agalsidase beta treatment beneficial in Fabry's disease

April 12, 2010

Sanofi-aventis obtains exclusive worldwide license for new regenerative diabetes therapeutic

April 9, 2010

Health Canada approves Seasonique contraceptive

April 9, 2010

Merck & Co.'s new BB3 agonist reduces weight in obesity model

April 9, 2010

Leptin therapy proves advantageous in mouse model of type 1 diabetes

April 9, 2010

Arena Pharmaceuticals and Merck & Co. claim new GPR81 agonists

April 9, 2010

New dipeptidyl peptidase 4 inhibitors discovered by Cadila Pharmaceuticals

April 9, 2010

Recordati signs marketing agreement with Esteve for pitavastatin

April 8, 2010

Living Cell Technologies' phase I/IIa Diabecell trial in type 1 diabetes meets endpoints

April 8, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...